Small Dense Low‐Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients

Mohammad Bilal Siddiqui, Tamoore Arshad, Samarth Patel, Emily Lee, Somaya Albhaisi, Arun J. Sanyal, R. Todd Stravitz, Carolyn Driscoll, Richard K. Sterling, Trevor Reichman, Chandra Bhati, Mohammad Shadab Siddiqui – 23 January 2019 – Cardiovascular disease (CVD) is an important cause of morbidity and mortality after liver transplantation (LT). Although LT is associated with dyslipidemia, particularly atherogenic lipoprotein subparticles, the impact of these subparticles on CVD‐related events is unknown.

A Large‐Scale Multicenter Study Validates Aldo‐Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma

Xu Ye, Cunyan Li, Xuyu Zu, Minglin Lin, Qiang Liu, Jianghua Liu, Guoguo Xu, Zhiyong Chen, Yongliang Xu, Long Liu, Diteng Luo, Zhe Cao, Guiyuan Shi, Zirui Feng, Hongyu Deng, Qianjin Liao, Chuan Cai, Duan‐Fang Liao, Jing Wang, Junfei Jin, Deliang Cao – 23 January 2019 – Aldo‐keto reductase family 1 member B10 (AKR1B10) is a secretory protein overexpressed in hepatocellular carcinoma (HCC). We aimed to evaluate AKR1B10 as a serum marker for detection of HCC.

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis

Akira Hiramatsu, Hiroshi Aikata, Shinsuke Uchikawa, Kazuki Ohya, Kenichiro Kodama, Yuno Nishida, Kana Daijo, Mitsutaka Osawa, Yuji Teraoka, Fumi Honda, Yuki Inagaki, Kei Morio, Reona Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Michio Imamura, Junko Tanaka, Kazuaki Chayama – 22 January 2019 – Although the effect of levocarnitine (L‐carnitine) on hyperammonemia has been reported in patients with liver cirrhosis (LC), its effect on sarcopenia remains to be elucidated.

Left Ventricular Longitudinal Contractility Predicts Acute‐on‐Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt

Christian Jansen, Anna Schröder, Robert Schueler, Jennifer Lehmann, Michael Praktiknjo, Frank E. Uschner, Robert Schierwagen, Daniel Thomas, Sofia Monteiro, Georg Nickenig, Christian P. Strassburg, Carsten Meyer, Vicente Arroyo, Christoph Hammerstingl, Jonel Trebicka – 22 January 2019 – Acute deterioration of liver cirrhosis (e.g., infections, acute‐on‐chronic liver failure [ACLF]) requires an increase in cardiac contractility. The insufficiency to respond to these situations could be deleterious.

Direct Inhibition of Hepatitis B e Antigen by Core Protein Allosteric Modulator

Zhipeng Yan, Daitze Wu, Hui Hu, Jing Zeng, Xin Yu, Zhiheng Xu, Zheng Zhou, Xue Zhou, Guang Yang, John A.T. Young, Lu Gao – 21 January 2019 – Hepatitis B e antigen (HBeAg) is an important immunomodulator for promoting host immune tolerance during chronic hepatitis B (CHB) infection. In patients with CHB, HBeAg loss and seroconversion represent partial immune control of CHB infection and are regarded as valuable endpoints. However, the current approved treatments have only a limited efficacy in achieving HBeAg seroconversion in HBeAg‐positive patients.

Identification of Polycystic Kidney Disease 1 Like 1 Gene Variants in Children With Biliary Atresia Splenic Malformation Syndrome

John‐Paul Berauer, Anya I. Mezina, David T. Okou, Aniko Sabo, Donna M. Muzny, Richard A. Gibbs, Madhuri R. Hegde, Pankaj Chopra, David J. Cutler, David H. Perlmutter, Laura N. Bull, Richard J. Thompson, Kathleen M. Loomes, Nancy B. Spinner, Ramakrishnan Rajagopalan, Stephen L. Guthery, Barry Moore, Mark Yandell, Sanjiv Harpavat, John C. Magee, Binita M. Kamath, Jean P. Molleston, Jorge A. Bezerra, Karen F. Murray, Estella M. Alonso, Philip Rosenthal, Robert H. Squires, Kasper S. Wang, Milton J. Finegold, Pierre Russo, Averell H. Sherker, Ronald J. Sokol, Saul J.

Deficiency of Both Farnesoid X Receptor and Takeda G Protein–Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice

Jessica M. Ferrell, Preeti Pathak, Shannon Boehme, Tricia Gilliland, John Y. L. Chiang – 21 January 2019 – Activation of the nuclear bile acid receptor farnesoid X receptor (FXR) protects against hepatic inflammation and injury, while Takeda G protein–coupled receptor 5 (TGR5) promotes adipose tissue browning and energy metabolism. Here, we examined the physiological and metabolic effects of the deficiency of these two bile acid receptors on hepatic metabolism and injury in mice. Fxr/Tgr5 double knockout mice (DKO) were generated for metabolic phenotyping.

Efficacy of Granulocyte Colony‐stimulating Factor in the Management of Steroid‐Nonresponsive Severe Alcoholic Hepatitis: A Double‐Blind Randomized Controlled Trial

Saggere Muralikrishna Shasthry, Manoj Kumar Sharma, Varsha Shasthry, Apurva Pande, Shiv Kumar Sarin – 21 January 2019 – Severe alcoholic hepatitis (SAH) is often a progressive disease with high mortality and limited steroid responsiveness. Management options of steroid nonresponsive SAH (day 7 Lille score > 0.45) are limited. We assessed the efficacy and safety of granulocyte colony‐stimulating factor (G‐CSF) in steroid nonresponders.

E‐cigarettes and Western Diet: Important Metabolic Risk Factors for Hepatic Diseases

Kamrul M. Hasan, Theodore C. Friedman, Xuesi Shao, Meher Parveen, Carl Sims, Desean L. Lee, Jorge Espinoza‐Derout, Indrani Sinha‐Hikim, Amiya P. Sinha‐Hikim – 21 January 2019 – The use of electronic nicotine delivery systems (ENDS), also known as e‐cigarettes, with a variety of e‐liquids/e‐juices, is increasing at an alarming rate among adolescents who do not realize the potential harmful health effects. This study examines the harmful effects of ENDS on the liver.

Subscribe to